InvestSMART

4DMedical Limited (ASX: 4DX) - Announcements

Current share price for 4DX : $3.480 0.02 (0.58%)+

ASX company news and announcements for 4DMedical Limited (4DX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All 4DMedical Limited (4DX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than 4DMedical Limited (4DX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for 4DMedical Limited (4DX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,093 FY2025 Full year results 29 Aug 2025 9:46AM $0.480 $3.480 risen by 625%
$2,093 FY2025 Full year results 29 Aug 2025 9:46AM $0.480 $3.480 risen by 625%
$2,093 Appendix 4E - Preliminary Final Report 29 Aug 2025 9:42AM $0.480 $3.480 risen by 625%
$2,093 Appendix 4E - Preliminary Final Report 29 Aug 2025 9:42AM $0.480 $3.480 risen by 625%
$2,093 Notification regarding unquoted securities - 4DX 28 Aug 2025 3:07PM $0.480 $3.480 risen by 625%
$2,093 Application for quotation of securities - 4DX 28 Aug 2025 3:01PM $0.480 $3.480 risen by 625%
$2,093 4DMedical secures $10m strategic investment from Pro Medicus 31 Jul 2025 4:53PM $0.240 $3.480 risen by 1,350%
$2,093 Proposed issue of securities - 4DX 31 Jul 2025 4:41PM $0.240 $3.480 risen by 1,350%
$2,093 Quarterly Activity Report and Appendix 4C 31 Jul 2025 4:38PM $0.240 $3.480 risen by 1,350%
$2,093 Proposed issue of securities - 4DX 28 Jul 2025 3:44PM $0.245 $3.480 risen by 1,320.41%
$2,093 4DMedical renews 3 year contract with University of Michigan 18 Jul 2025 9:42AM $0.250 $3.480 risen by 1,292%
$2,093 Change of Director's Interest Notice - AF 8 Jul 2025 3:39PM $0.240 $3.480 risen by 1,350%
$2,093 Cleansing Notice 3 Jul 2025 1:45PM $0.245 $3.480 risen by 1,320.41%
$2,093 Notification of cessation of securities - 4DX 3 Jul 2025 1:27PM $0.245 $3.480 risen by 1,320.41%
$2,093 Application for quotation of securities - 4DX 3 Jul 2025 1:22PM $0.245 $3.480 risen by 1,320.41%
$2,093 4DMedical contract with Stanford, includes CTVQ 17 Jun 2025 8:53AM $0.265 $3.480 risen by 1,213.21%
$2,093 Olympus launches new SeleCT Screening campaign 11 Jun 2025 8:51AM $0.300 $3.480 risen by 1,060%
$2,093 Application for quotation of securities - 4DX 10 Jun 2025 11:40AM $0.295 $3.480 risen by 1,079.66%
$2,093 Cleansing Notice 30 May 2025 2:00PM $0.340 $3.480 risen by 923.53%
$2,093 Application for quotation of securities - 4DX 29 May 2025 10:30AM $0.350 $3.480 risen by 894.29%
$2,093 Investor Presentation - FDA Submission for CTVQ 27 May 2025 10:57AM $0.300 $3.480 risen by 1,060%
$2,093 4DMedical files FDA submission for CTVQ 26 May 2025 9:20AM $0.260 $3.480 risen by 1,238.46%
$2,093 4DMedical wins commercial contract with Intermountain Health 5 May 2025 9:50AM $0.295 $3.480 risen by 1,079.66%
$2,093 Top 20 Option Holders & Distribution Schedule 2 May 2025 12:00PM $0.305 $3.480 risen by 1,040.98%
$2,093 Application for quotation of securities - 4DX 2 May 2025 11:49AM $0.300 $3.480 risen by 1,060%

176 - 200 of 596 results

Page 8 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.